|
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Oct 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Jun 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
Apr 2019 |
Blood |
Aplastic Anemia |
|
Eltrombopag in children with severe aplastic anemia |
Apr 2021 |
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
|
Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia |
Apr 2021 |
Transplantation and Cellular Therapy |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
|
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
Jan 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
Feb 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
May 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
